膀胱癌的全身治疗
Systemic therapy in bladder cancer.
作者信息
Pinto Ian G
机构信息
Department of Hematology and Medical Oncology, Sir H. N. Reliance Foundation Hospital and Research Centre, Mumbai, Maharashtra, India.
出版信息
Indian J Urol. 2017 Apr-Jun;33(2):118-126. doi: 10.4103/iju.IJU_294_16.
Abstract
Systemic chemotherapy is essential for the management of muscle-invasive bladder cancer (MIBC) and metastatic bladder cancer (BCa). Neoadjuvant chemotherapy is key to the management of MIBC with many cisplatin-based regimens. Adjuvant chemotherapy may be considered for selected patients who did not receive neoadjuvant therapy. Systemic chemotherapy with radiotherapy is a critical component of a trimodal bladder-preserving approach and is superior to radiotherapy alone. Cisplatin-based chemotherapy has been the mainstay for metastatic BCa. Immunotherapy in the form of checkpoint inhibitors is a promising new drug for the treatment of BCa. Molecular characterization of each individual BCa is likely to lead to a target-directed therapeutic revolution.
摘要
全身化疗对于肌层浸润性膀胱癌（MIBC）和转移性膀胱癌（BCa）的治疗至关重要。新辅助化疗是许多基于顺铂方案治疗MIBC的关键。对于未接受新辅助治疗的特定患者，可考虑辅助化疗。全身化疗联合放疗是三联保膀胱治疗方法的关键组成部分，且优于单纯放疗。基于顺铂的化疗一直是转移性BCa的主要治疗方法。以检查点抑制剂形式存在的免疫疗法是一种有前景的治疗BCa的新药。对每个个体的BCa进行分子特征分析可能会引发靶向治疗革命。
相似文献
1
Systemic therapy in bladder cancer.膀胱癌的全身治疗
Indian J Urol. 2017 Apr-Jun;33(2):118-126. doi: 10.4103/iju.IJU_294_16.
2
Improving Systemic Chemotherapy for Bladder Cancer.改善膀胱癌的全身化疗
Curr Oncol Rep. 2016 May;18(5):27. doi: 10.1007/s11912-016-0512-2.
3
Neoadjuvant and adjuvant treatments in muscle-invasive bladder cancer: Where are we?肌肉浸润性膀胱癌的新辅助治疗和辅助治疗：我们目前的进展如何？
Arch Esp Urol. 2020 Dec;73(10):971-985.
4
Perioperative Immunotherapy in Muscle-Invasive Bladder Cancer.肌层浸润性膀胱癌的围手术期免疫治疗。
Curr Treat Options Oncol. 2023 Sep;24(9):1213-1230. doi: 10.1007/s11864-023-01113-z. Epub 2023 Jul 10.
5
Systemic therapy issues: Immunotherapy in nonmetastatic urothelial cancer.全身治疗问题：非转移性尿路上皮癌的免疫治疗
Urol Oncol. 2023 Jan;41(1):27-34. doi: 10.1016/j.urolonc.2020.10.004. Epub 2020 Oct 23.
6
Perioperative systemic therapy in muscle invasive bladder cancer: Current standard method, biomarkers and emerging strategies.肌层浸润性膀胱癌的围手术期全身治疗：当前的标准方法、生物标志物和新兴策略。
Investig Clin Urol. 2023 May;64(3):202-218. doi: 10.4111/icu.20230006.
7
Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy.原发性和继发性肌层浸润性膀胱癌之间的基因组差异是基于顺铂为基础的新辅助化疗疗效差异的基础。
Eur Urol. 2019 Feb;75(2):231-239. doi: 10.1016/j.eururo.2018.09.002. Epub 2018 Oct 2.
8
Avelumab as neoadjuvant therapy in patients with urothelial non-metastatic muscle invasive bladder cancer: a multicenter, randomized, non-comparative, phase II study (Oncodistinct 004 - AURA trial).阿维鲁单抗作为尿路上皮非转移性肌肉浸润性膀胱癌患者的新辅助治疗：一项多中心、随机、非对照的II期研究（Oncodistinct 004 - AURA试验）。
BMC Cancer. 2021 Dec 2;21(1):1292. doi: 10.1186/s12885-021-08990-3.
9
Guideline on Muscle-Invasive and Metastatic Bladder Cancer (European Association of Urology Guideline): American Society of Clinical Oncology Clinical Practice Guideline Endorsement.肌层浸润性和转移性膀胱癌指南（欧洲泌尿外科学会指南）：美国临床肿瘤学会临床实践指南认可。
J Clin Oncol. 2016 Jun 1;34(16):1945-52. doi: 10.1200/JCO.2015.65.9797. Epub 2016 Mar 21.
10
Emerging perioperative therapeutic approaches in muscle invasive bladder cancer.肌肉浸润性膀胱癌围手术期的新兴治疗方法。
Ther Adv Urol. 2022 Oct 28;14:17562872221134389. doi: 10.1177/17562872221134389. eCollection 2022 Jan-Dec.
引用本文的文献
1
Metastasis development in non-muscle-invasive bladder cancer.非肌层浸润性膀胱癌中的转移发展
Nat Rev Urol. 2024 Nov 20. doi: 10.1038/s41585-024-00963-y.
2
PARP inhibitors chemopotentiate and synergize with cisplatin to inhibit bladder cancer cell survival and tumor growth.聚腺苷二磷酸核糖聚合酶抑制剂与顺铂联合具有化学增敏作用，可抑制膀胱癌细胞的存活和肿瘤生长。
BMC Cancer. 2022 Mar 23;22(1):312. doi: 10.1186/s12885-022-09376-9.
3
The therapeutic and prognostic implications of molecular biomarkers in urothelial carcinoma.分子生物标志物在尿路上皮癌中的治疗及预后意义
Transl Cancer Res. 2020 Oct;9(10):6609-6623. doi: 10.21037/tcr-20-1243.
4
MicroRNA-325 Is a Potential Biomarker and Tumor Regulator in Human Bladder Cancer.微小RNA-325是人类膀胱癌中的一种潜在生物标志物和肿瘤调节因子。
Technol Cancer Res Treat. 2018 Jan 1;17:1533033818790536. doi: 10.1177/1533033818790536.
5
RON is overexpressed in bladder cancer and contributes to tumorigenic phenotypes in 5637 cells.RON在膀胱癌中过表达，并导致5637细胞中的致瘤表型。
Oncol Lett. 2018 May;15(5):6547-6554. doi: 10.3892/ol.2018.8135. Epub 2018 Feb 28.
6
Identification of differentially expressed genes and biological pathways in bladder cancer.膀胱癌差异表达基因及通路的鉴定。
Mol Med Rep. 2018 May;17(5):6425-6434. doi: 10.3892/mmr.2018.8711. Epub 2018 Mar 9.
7
What's inside.里面有什么。
Indian J Urol. 2017 Apr-Jun;33(2):99-100. doi: 10.4103/iju.IJU_96_17.
本文引用的文献
1
Multicenter Prospective Phase II Trial of Neoadjuvant Dose-Dense Gemcitabine Plus Cisplatin in Patients With Muscle-Invasive Bladder Cancer.多中心前瞻性 II 期试验：新辅助剂量密集型吉西他滨联合顺铂治疗肌层浸润性膀胱癌。
J Clin Oncol. 2018 Jul 1;36(19):1949-1956. doi: 10.1200/JCO.2017.75.0158. Epub 2018 May 9.
2
Phase III, Double-Blind, Randomized Trial That Compared Maintenance Lapatinib Versus Placebo After First-Line Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 1/2-Positive Metastatic Bladder Cancer.一项比较转移性膀胱癌表皮生长因子受体 1/2 阳性患者一线化疗后维持拉帕替尼与安慰剂的 III 期、双盲、随机试验。
J Clin Oncol. 2017 Jan;35(1):48-55. doi: 10.1200/JCO.2015.66.3468. Epub 2016 Oct 28.
3
Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends.膀胱癌发病率和死亡率：全球概述及最新趋势。
Eur Urol. 2017 Jan;71(1):96-108. doi: 10.1016/j.eururo.2016.06.010. Epub 2016 Jun 28.
4
Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis.肌肉浸润性膀胱癌的新辅助化疗：系统评价和两步荟萃分析
Oncologist. 2016 Jun;21(6):708-15. doi: 10.1634/theoncologist.2015-0440. Epub 2016 Apr 6.
5
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial.阿替利珠单抗用于接受铂类化疗后病情进展的局部晚期和转移性尿路上皮癌患者：一项单臂、多中心、2期试验。
Lancet. 2016 May 7;387(10031):1909-20. doi: 10.1016/S0140-6736(16)00561-4. Epub 2016 Mar 4.
6
Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial.多西他赛单药或联合雷莫芦单抗或伊立替康治疗局部晚期或转移性尿路上皮癌的二线治疗：一项开放标签、三臂、随机对照的 II 期试验。
J Clin Oncol. 2016 May 1;34(13):1500-9. doi: 10.1200/JCO.2015.65.0218. Epub 2016 Feb 29.
7
Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer.局部晚期膀胱癌辅助化疗的疗效。
J Clin Oncol. 2016 Mar 10;34(8):825-32. doi: 10.1200/JCO.2015.64.1076. Epub 2016 Jan 19.
8
Single-agent Taxane Versus Taxane-containing Combination Chemotherapy as Salvage Therapy for Advanced Urothelial Carcinoma.单药紫杉烷与含紫杉烷联合化疗作为晚期尿路上皮癌挽救治疗的对比
Eur Urol. 2016 Apr;69(4):634-641. doi: 10.1016/j.eururo.2015.07.042. Epub 2015 Aug 8.
9
Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer.吉西他滨联合顺铂与甲氨蝶呤、长春碱、多柔比星联合顺铂作为肌层浸润性膀胱癌新辅助治疗的疗效比较。
Cancer. 2015 Aug 1;121(15):2586-93. doi: 10.1002/cncr.29387. Epub 2015 Apr 14.
10
The safety and efficacy of single-agent pemetrexed in platinum-resistant advanced urothelial carcinoma: a large single-institution experience.培美曲塞单药治疗铂类耐药晚期尿路上皮癌的安全性和疗效：一项大型单机构经验。
Oncologist. 2015 May;20(5):508-15. doi: 10.1634/theoncologist.2014-0354. Epub 2015 Apr 6.
Zotero 插件